Erenumab for epilepsy

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Mar 2017: Trial started, NCT03096834
  2. 30 Mar 2017: Trial registered, NCT03096834

The trials

NCT03096834: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

State
Completed
Phase
Phase 3
People
246 taking part
Started
20 Mar 2017
Primary completion
18 Jan 2018
Arms
AMG334 140 mg DB, AMG334 140 mg DB cont on AMG334 140 mg, Placebo in DB to AMG334 140 mg
Results
Posted on the registry
  1. 20 Mar 2017: Trial started
  2. 30 Mar 2017: Trial registered
  3. 28 Jan 2021: Trial completed
  4. 18 Feb 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as AMG334 (70 mg) Pre-Filled Syringe (PFS), Erenumab AI/Pen, Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Erenumab PFS, erenumab 70mg/mL.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.